Viatris Could Soon Make a Generic Ozempic, But Does That Make It a Buy?
Viatris Inc.
WKN: A2QAME / Symbol: VTRS / Name: Viatris / Aktie / Pharmazeutika / Mid Cap /
13,44 €
-1,39 %
Viatris Could Soon Make a Generic Ozempic, But Does That Make It a Buy?
Viatris (NASDAQ: VTRS) could be on the verge of eating the lunch of Novo Nordisk's (NYSE: NVO) two golden cash cows: The diabetes drug Ozempic, and another version that's formulated for weight loss
Der Beitrag wird untersucht



Neueste Beiträge
KacperGorecki in What Are the Top Casino Companies?